Atherotech Diagnostics Lab Adds Corgenix AspirinWorks® Test for Aspirin Effect
Atherotech Diagnostics Lab Adds Corgenix AspirinWorks ® Test for Aspirin Effect
AspirinWorks ® Test measures levels of inflammatory chemical thromboxane, which can interfere with heart-protective effect of aspirin therapy
DENVER--(BUSINESS WIRE)-- Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that Atherotech Diagnostics Lab will carry its AspirinWorks® Test for determining aspirin effect.
Under terms of the agreement, Corgenix' AspirinWorks product will be used to assess aspirin effect as part of Atherotech Diagnostic Lab's cardiometabolic testing products. AspirinWorks is the only U.S. FDA-cleared test that measures the urinary biomarker 11-dehydro thromboxane B2 (11dhTxB2) to determine aspirin effect.
"Atherotech is one of the nation's most recognized and respected labs for comprehensive cardiometabolic testing and cardiovascular risk assessment," said Douglass Simpson, Corgenix' President and Chief Executive Officer. "Atherotech's access to the U.S. primary care market further strengthens the AspirinWorks product, a test that has proven its clinical utility by measuring aspirin effect, thereby enabling physicians to identify an additional influence on aspirin's ability to aid in reducing heart attack and stroke risk."
The AspirinWorks Test identifies those individuals who have elevated thromboxane levels despite taking a daily aspirin dose, with studies showing up to 25 percent of individuals not seeing the expected beneficial effects of aspirin. The thromboxane metabolite 11dhTxB2 identified by AspirinWorks has been clinically validated through extensive research and numerous well-designed and well-powered clinical trials. The AspirinWorks 11dhTxB2 Test is FDA-cleared and used by thousands of physicians to test and guide treatment for hundreds of thousands of patients each year worldwide.
Atherotech provides a full complement of more than 60 routine and specialty diagnostic tests, including its patented VAP Lipid Panel®, to help physicians establish the most effective course of treatment from a single source.
About the AspirinWorks Test
Launched in the U.S. in June 2007 following FDA 510(k) clearance, the AspirinWorks Test is available nationwide through major medical laboratories. Unlike functional platelet tests, which require freshly drawn blood that must be evaluated within at least four hours, the AspirinWorks Test is performed on a random urine sample that can be obtained in any doctor's office or patient service center, making the test convenient for both physician and patient. More information is also available at www.aspirinworks.com .
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience in product submissions to the FDA and other worldwide regulatory authorities. Additionally Corgenix contract develops and manufactures products for key medical and life science companies in state-of-the-art facilities in Colorado. The company operates under a Quality Management System that is ISO 13485:2012 certified and compliant with FDA regulations. More information is available at www.corgenix.com .
Corgenix Medical Corp.
Senior Vice President Operations and Finance and Chief Financial Officer
Armada Medical Marketing
Vice President, Public Relations
Phone: 303-623-1190 x 230
KEYWORDS: United States North America Colorado
The article Atherotech Diagnostics Lab Adds Corgenix AspirinWorks® Test for Aspirin Effect originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.